Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved Keytruda, the company’s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.
![Maak saaie content interessant: spelen met invalshoeken [3 tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/01/high-angle-shot-of-a-diverse-business-team-hands-p-2023-11-27-05-19-55-utc-1-80x60.jpg)
